Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Thoracic Malignancies
How would you manage persistent chest wall disease after adjuvant chemoRT s/p lobectomy for T3N0 NSCLC with an involved margin?
Related Questions
How would you address squamous cell carcinoma in situ focally present at the bronchial margin after lobectomy?
Would you offer empiric radiation for a growing mediastinal mass radiographically suspicious for thymoma in a patient who declines surgery?
How does a history of radiation pneumonitis impact your decision on future lung SBRT?
Would you recommend post op radiation therapy for a primary pulmonary synovial sarcoma which underwent lobectomy?
Which patients with primary, early-stage NSCLC would you utilize immunotherapy in conjunction with SBRT?
What is the role for molecular agents alone for medically inoperable NSCLC who is not a good candidate for chemoRT?
When do you offer SBRT for a small, slowly growing lung lesion?
How would you manage out-of-field nodal recurrence of NSCLC post definitive CRT and adjuvant immunotherapy?
For NSCLC patients who are polymetastatic who then become and remain oligometastatic, is there a role for local ablative RT to the primary and metastatic sites?
What BED10 do you aim for when prescribing hypofractionated treatment for ultra-central tumors of the lung?
